UBS Group
ETON icon

UBS Group’s Eton Pharmaceutcials ETON Stock Holding History

UBS Group’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.37M Sell
65,424
-103,534
-61% -$3.04M ﹤0.01% 4966
2026
Q1 		$4.17M Buy
168,958
+42,284
+33% +$739K ﹤0.01% 4257
2025
Q4 		$2.14M Sell
126,674
-93,687
-43% -$1.65M ﹤0.01% 4921
2025
Q3 		$4.79M Buy
220,361
+7,877
+4% +$131K ﹤0.01% 4084
2025
Q2 		$3.03M Buy
212,484
+116,736
+122% +$1.85M ﹤0.01% 4394
2025
Q1 		$1.24M Sell
95,748
-39,604
-29% -$598K ﹤0.01% 5085
2024
Q4 		$1.8M Buy
135,352
+116,335
+612% +$1.18M ﹤0.01% 4819
2024
Q3 		$114K Buy
19,017
+7,999
+73% +$33.8K ﹤0.01% 6256
2024
Q2 		$36.2K Buy
11,018
+9,058
+462% +$31.7K ﹤0.01% 6933
2024
Q1 		$7.35K Sell
1,960
-1,792
-48% -$7.83K ﹤0.01% 7392
2023
Q4 		$16.4K Buy
3,752
+2,830
+307% +$11.3K ﹤0.01% 7226
2023
Q3 		$3.85K Buy
+922
New +$3.56K ﹤0.01% 7506
2023
Q2 		– Sell
-5,387
Closed -$20.7K – 9100
2023
Q1 		$20.7K Buy
5,387
+1,448
+37% +$5.28K ﹤0.01% 7047
2022
Q4 		$11.1K Sell
3,939
-2,494
-39% -$6.71K ﹤0.01% 8437
2022
Q3 		$14K Buy
6,433
+2,665
+71% +$6.64K ﹤0.01% 7901
2022
Q2 		$10K Sell
3,768
-787
-17% -$2.64K ﹤0.01% 7955
2022
Q1 		$20K Buy
4,555
+476
+12% +$1.87K ﹤0.01% 7445
2021
Q4 		$17K Buy
+4,079
New +$19.5K ﹤0.01% 8058
2021
Q3 		– Sell
-5,363
Closed -$33K – 9684
2021
Q2 		$33K Buy
5,363
+871
+19% +$6.45K ﹤0.01% 6825
2021
Q1 		$33K Sell
4,492
-1,053
-19% -$8.98K ﹤0.01% 6923
2020
Q4 		$45K Buy
5,545
+1,541
+38% +$11.9K ﹤0.01% 6279
2020
Q3 		$32K Sell
4,004
-779
-16% -$5.32K ﹤0.01% 5944
2020
Q2 		$26K Sell
4,783
-1,948
-29% -$9.67K ﹤0.01% 6373
2020
Q1 		$28K Buy
6,731
+4,181
+164% +$24.4K ﹤0.01% 6267
2019
Q4 		$18K Buy
+2,550
New +$15.8K ﹤0.01% 6934
2019
Q3 		– Sell
-1,189
Closed -$9K – 8059
2019
Q2 		$9K Sell
1,189
-7,353
-86% -$57.1K ﹤0.01% 7123
2019
Q1 		$68K Buy
+8,542
New +$59.3K ﹤0.01% 5336

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

UBS Group's ETON Position: Q2 2026 in Review

UBS Group reduced its Eton Pharmaceutcials (ETON) stake by 61% in Q2 2026, selling an estimated $3.04M and leaving 65,424 shares worth $2.37M. The position accounts for ﹤0.01% of the portfolio, ranked #4966.

UBS Group first reported a position in ETON in Q1 2019 and has held it in 27 quarters since. The position peaked at $4.79M in Q3 2025. 164 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • UBS Group held 65,424 shares of Eton Pharmaceutcials worth $2.37M as of Q2 2026.
  • UBS Group sold 103,534 Eton Pharmaceutcials shares in Q2 2026, an estimated $3.04M.
  • Eton Pharmaceutcials made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4966 holding.
  • UBS Group first reported a position in Eton Pharmaceutcials in Q1 2019 and has held it in 27 quarters since.
  • UBS Group's Eton Pharmaceutcials position peaked at $4.79M in Q3 2025.
  • 164 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.